Cagrilintide Research Overview (also known as CagriSema)
A long-acting amylin analog studied for its effects on appetite regulation, satiety signaling, and metabolic markers. Targets amylin receptors in the hypothalamus, producing complementary appetite-suppressive effects to GLP-1 agonists. Under investigation in combination with semaglutide (CagriSema) for synergistic weight-loss benefits.
What Is Cagrilintide?
Cagrilintide is a long-acting synthetic analog of amylin — a pancreatic peptide hormone co-secreted with insulin by beta cells in response to meals. Developed by Novo Nordisk, it is engineered for once-weekly subcutaneous dosing and is being studied both as a standalone weight-loss agent and in combination with semaglutide (called CagriSema).
Mechanism of Action
Amylin acts through amylin receptors primarily in the area postrema and nucleus of the solitary tract — regions that regulate satiety. It slows gastric emptying, reduces postprandial glucagon secretion, and suppresses appetite through central mechanisms distinct from GLP-1 pathways. Cagrilintide replicates these effects with a dramatically extended half-life, enabling once-weekly dosing.
Clinical Development
Phase 2 trials demonstrated dose-dependent weight loss of up to 10.8% body weight over 26 weeks. The combination with semaglutide (CagriSema) has shown mean weight reductions approaching 22–25% body weight in Phase 3 REDEFINE trials — approaching the efficacy of bariatric surgery through complementary, largely non-overlapping hormonal mechanisms.
Quick Reference
| Literature-Reported Dose Range | 2.4 mg weekly (after 16-week dose escalation) |
| Literature-Reported Frequency | Once weekly, same day each week |
| Literature-Reported Cycle Length | Continuous treatment recommended for sustained effects |
| Literature-Reported Washout | Not applicable - continuous therapy for optimal efficacy |
| Storage | Store frozen at -20°C, protect from light, do not shake |
| Sites Reported in Studies | Subcutaneous: abdomen, thigh, or upper arm (rotate weekly) |
| Timing | Same day weekly, preferably evening, with or without food |
Research Indications
Weight Loss
Superior Obesity Treatment
Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination, outperforming existing therapies
Type 2 Diabetes Weight Management
15.7% weight loss in diabetic patients with concurrent glycemic improvements
Sustained Weight Maintenance
Long-acting formulation supports sustained weight loss throughout treatment period
Metabolic
Glucose Control Enhancement
Phase 2 trials show 2.2% HbA1c reduction with CagriSema combination versus semaglutide alone
Insulin Sensitivity Improvement
Amylin receptor activation enhances insulin sensitivity and glucose metabolism
Gastric Emptying Regulation
Controlled gastric emptying improves postprandial glucose control and satiety
Appetite Control
Dual Pathway Satiety
Amylin and calcitonin receptor activation provides robust appetite suppression via hindbrain pathways
Food Preference Modulation
Central nervous system effects influence food choices and eating behaviors
Early Satiation Induction
Promotes feeling of fullness with smaller meal portions, supporting caloric restriction
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Weight Loss (Monotherapy) | 2.4 mg weekly | Once weekly | SubQ |
| Weight Loss (CagriSema) | 2.4 mg + semaglutide 2.4 mg | Once weekly | SubQ |
| Type 2 Diabetes Management | 2.4 mg weekly | Once weekly | SubQ with metformin |
| Dose Escalation Protocol | 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg | Weekly increases over 16 weeks | SubQ |
| Combination Diabetes Therapy | 2.4 mg + SGLT2 inhibitor | Once weekly | SubQ |
| Cardiovascular Risk Reduction | 2.4 mg weekly | Once weekly | SubQ (REDEFINE 3 trial) |
Timing
Recommended administration window: same day weekly, preferably evening, with or without food. Typical onset: initial effects: 1-2 weeks; Significant weight loss: 4-12 weeks; Peak effects: 26+ weeks.
Peptide Interactions
CagriSema combination demonstrates enhanced weight loss (22.7% vs 16.1% semaglutide alone) and improved glycemic control through complementary GLP-1 and amylin pathways.
No known direct interactions. Both are effective weight loss agents with different mechanisms - cagrilintide targets amylin/calcitonin receptors while tirzepatide targets GLP-1/GIP receptors.
Both cause significant GI effects (gastroparesis, nausea). Cagrilintide (amylin agonist) and Retatrutide (triple GLP-1/GIP/glucagon agonist) have different mechanisms but compounded GI side effects create substantial risk. Not recommended without specialist supervision.
Phase 2 trials show similar efficacy profiles with no adverse interactions. Both GLP-1 agonists and amylin analogs work through distinct satiety pathways.
Monitor glucose levels closely as cagrilintide affects gastric emptying and may alter insulin absorption timing. May require insulin dose adjustments in diabetic patients.
Well-tolerated combination demonstrated in Phase 2/3 trials. No pharmacokinetic interactions observed between cagrilintide and metformin.
Clinical trials included patients on SGLT2 inhibitors with no safety concerns. Both mechanisms complement each other for diabetes and weight management.
Both are amylin receptor agonists with overlapping mechanisms. Combination would provide no additional benefit and may increase risk of gastrointestinal side effects.
Delayed gastric emptying may affect absorption of oral contraceptives. Space administration by 1 hour before cagrilintide injection.
Reported Research Timeline
01Week 1–2 (reported in cited studies): gastrointestinal adaptation period, mild nausea possible during dose escalation
02Week 4–8 (reported in cited studies): early weight loss becomes apparent (2-5%), appetite reduction noticeable
03Week 12–26 (reported in cited studies): significant weight loss acceleration (10-15%), improved satiety signals
04Week 26+ (reported in cited studies): peak efficacy achieved (15-23% weight loss), sustained weight loss maintenance with continued therapy
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Most common side effects are gastrointestinal (nausea, vomiting, diarrhea) during initial weeks
Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy
No clinically significant QT prolongation observed in thorough QT studies
Only 57.3% of patients achieved maximum 2.4 mg dose in REDEFINE 1 trial
Seek Medical Attention If:
Severe persistent nausea or vomiting preventing adequate hydration
Signs of pancreatitis (severe abdominal pain radiating to back)
Severe allergic reactions or anaphylaxis
Significant injection site reactions or abscess formation
Quality Indicators
Verified Marker
Pre-filled pen design
When approved, will likely be available as convenient pre-filled pen similar to other Novo Nordisk products
Verified Marker
Pharmaceutical grade purity
Clinical trial material demonstrates >98% purity with appropriate lipidation and folding
Verified Marker
Frozen storage stability
Proper frozen storage at -20°C maintains stability of lipidated peptide structure
Verified Marker
Extended stability profile
Long-acting formulation provides stable pharmacokinetics over 7-day dosing interval
Quality Concern
Aggregation or precipitation
Any visible particles, cloudiness, or color changes indicate protein degradation
Quality Concern
Temperature excursions
Exposure to repeated freeze-thaw cycles or high temperatures can denature the peptide structure
Acceptable Range
Not yet commercially available
Currently only available in clinical trials - FDA approval expected Q1 2026
Research Citations
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey, W.T., Blüher, M., Contreras, C.K.O., et al., 2025, New England Journal of Medicine - Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M.J., Bajaj, H.S., Broholm, C., et al., 2025, New England Journal of Medicine - Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Frias, J.P., Auerbach, P., Bajaj, H.S., et al., 2023, The Lancet - Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau, D.C.W., Erichsen, L., Francisco, A.M., et al., 2021, The Lancet - Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Enebo, L.B., Berthelsen, K.K., Kankam, M., et al., 2021, The Lancet - Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Glastrup, S., Moser, C., et al., 2021, Journal of Medicinal Chemistry - Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
Cao, J., Gholamrezaie, L., Donnelly, D., et al., 2025, Nature Communications - Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants
Gabe, M.B.N., Sonne, N., Liu, L., et al., 2024, Diabetes, Obesity and Metabolism - Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Dutta, D., Nagendra, L., Harish, B.G., et al., 2024, Indian Journal of Endocrinology and Metabolism - Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio, A.M., Mullally, J.A., Frishman, W.H., 2024, Cardiology in Review - Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, 2025, N Engl J Med - Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Yao H, Zhang A, Li D, 2024, BMJ - Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies MJ, Bajaj HS, Broholm C, 2025, N Engl J Med - Weight management treatment in obesity
Rubio-Herrera MA, Mera-Carreiro S, 2025, Med Clin (Barc) - Amylin analogs for the treatment of obesity without diabetes: present and future
Panou T, Gouveri E, Popovic DS, 2024, Expert Rev Clin Pharmacol
Research Focus
Weight loss, Amylin receptor agonism, Appetite regulation, GLP-1 combination therapy, Obesity
Verified Vendors Carrying Cagrilintide
Frequently Asked Questions
What should researchers watch for with Cagrilintide?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Cagrilintide?
Week 1–2 (reported in cited studies): gastrointestinal adaptation period, mild nausea possible during dose escalation
How is Cagrilintide typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →